PSMA-PET/CT Scans for Prostate Cancer

Palo Alto (17 mi)

Dr. Heather A Jacene, MD - Boston, MA ...

Overseen byHeather Jacene

Age: 18+

Sex: Male

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 4

Waitlist Available

Sponsor: Brigham and Women's Hospital

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?The goal of this clinical trial is to learn if serial PSMA-PET/CT scans can be used to monitor response to therapy in metastatic hormone sensitive prostate cancer and can be potentially used to optimize future treatment approaches. The main questions it aims to answer are: What is the proportion of men with residual PSMA-avid disease on PET/CT scans after 6 months of treatment for metastatic hormone sensitive prostate cancer? Do the findings on PSMA-PET/CT scans after 6 months of treatment for metastatic hormone sensitive prostate cancer correlate with other markers of disease status, like PSA? Participants will: Receive standard of care treatment for metastatic hormone sensitive prostate cancer Undergo a PSMA-PET/CT scan before starting treatment Undergo a PSMA-PET/CT scan after 6 months of treatment Have a chart review every 3 months for 1 year after the 6 month PSMA-PET/CT scan

Eligibility Criteria

This trial is for men with metastatic hormone-sensitive prostate cancer. Participants will receive standard care and undergo PSMA-PET/CT scans before and after 6 months of treatment to track disease response.

Inclusion Criteria

I have confirmed prostate cancer, either through tests or clear clinical signs.

I am 18 years old or older.

I have metastatic hormone-sensitive prostate cancer without systemic therapy in the last 6 months.

I agree to use birth control or abstain from sex during and 24 hours after the PSMA-PET scans.

Exclusion Criteria

I am not on any cancer treatments except for hormone therapy or specific prostate cancer medications.

I have not had radiation to my prostate or any cancer spread sites before a 6-month PET scan.

I do not have any serious illnesses or social situations that would stop me from following the study's requirements.

Treatment Details

The study tests if serial PSMA-PET/CT scans can effectively monitor the response to therapy in patients with metastatic hormone-sensitive prostate cancer, aiming to improve future treatments.

1Treatment groups

Experimental Treatment

Group I: PSMA-PET/CT armExperimental Treatment2 Interventions

Patients will undergo 18F-rhPSMA-7.3 PSMA PET/CT scan before and after 6 months of treatment for metastatic hormone sensitive prostate cancer. Patients will undergo chart review every 3 months for 1 year after the second 18F-rhPSMA-7.3 PSMA PET/CT scan.